HALO Insider Sale: CFO Disposes 2,227 Shares Under 10b5-1 Plan

Rhea-AI Filing Summary

Nicole LaBrosse, SVP and Chief Financial Officer of Halozyme Therapeutics (HALO), reported two open-market sales of common stock on 09/22/2025 executed under a Rule 10b5-1 trading plan adopted on June 11, 2025. The Form 4 shows a sale of 1,913 shares at a weighted-average price of $77.827 (prices in the range $77.34–$78.32) and a sale of 314 shares at a weighted-average price of $78.667 (range $78.37–$79.18).

Following the reported transactions, the beneficial ownership reported was 22,079 shares (direct). The filing was signed on behalf of the reporting person by an attorney-in-fact on 09/23/2025. The Form 4 discloses that the sales were effected by a broker pursuant to the 10b5-1 plan and provides weighted-average price ranges with an offer to furnish per-price quantities on request.

Positive

• Sales executed under a Rule 10b5-1 plan, providing an affirmative defense and indicating pre-planned transactions
• Transparent disclosure of weighted-average prices and price ranges and offer to provide per-price share counts on request
• Timely Section 16 reporting with Form 4 filed and signed by attorney-in-fact

Negative

• Insider dispositions totaling 2,227 shares reduced the reporting person’s direct holdings
• No context on materiality of the holdings relative to total outstanding shares is provided in the filing

Insights

Securities Compliance Analyst

TL;DR: Sales were executed under a pre-established 10b5-1 plan, indicating planned dispositions rather than opportunistic trading.

The Form 4 clearly states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted June 11, 2025, which provides an affirmative defense against insider trading claims when conditions are met. The filing discloses weighted-average sale prices and price ranges and offers to provide per-price share counts upon request, improving transparency. The reported beneficial ownership after the transactions is documented as direct ownership of 22,079 shares. From a compliance perspective, the filing includes the typical necessary disclosures to demonstrate reliance on a trading plan and to satisfy Section 16 reporting obligations.

Financial Reporting Analyst

TL;DR: Modest insider sales reduced direct holdings slightly; transactions were small in absolute terms relative to institutional volumes.

The Form 4 records two open-market sales totaling 2,227 shares at weighted-average prices of $77.827 and $78.667. These are routine dispositions when executed under a 10b5-1 plan and do not include any derivative transactions or other non-routine events. The filing supplies the necessary quantities and price ranges and shows continuing direct ownership of 22,079 shares. There is no additional financial data in the filing to assess impact on company fundamentals.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LaBrosse Nicole

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2025		S(1)		1,913	D	$77.827(2)	22,393	D
Common Stock	09/22/2025		S(1)		314	D	$78.667(3)	22,079	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.

2. Represents a weighted average sales price per share. These shares were sold at prices ranging from $77.34 to $78.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. These shares were sold at prices ranging from $78.37 to $79.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

	/s/ James R. Oehler, Attorney-in-Fact	09/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Nicole LaBrosse (HALO) report on Form 4 filed 09/23/2025?

The Form 4 reports two open-market sales on 09/22/2025 totaling 2,227 shares executed under a Rule 10b5-1 plan; weighted-average prices were $77.827 and $78.667.

Were the sales under a pre-arranged trading plan or spontaneous trades?

The Form 4 states the sales were effected by a broker pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2025.

How many shares did the reporting person own after the transactions?

The filing shows direct beneficial ownership following the reported transactions of 22,079 shares.

What price ranges were the shares sold at according to the filing?

The filing discloses sale price ranges of $77.34–$78.32 for the first lot and $78.37–$79.18 for the second lot, with weighted averages shown.

Who signed the Form 4 and when was it signed?

The Form 4 was signed on behalf of the reporting person by James R. Oehler, Attorney-in-Fact on 09/23/2025.